Cetuximab (Cet) clearance and survival in patients (pts) with metastatic colorectal cancer (mCRC)

被引：1
|
作者：
Jiang, Di Maria
Sim, Hao-Wen
Siu, Lillian L.
Shapiro, Jeremy David
Liu, Geoffrey
Price, Timothy Jay
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 04期
关键词：
D O I：
10.1200/JCO.2017.35.4_suppl.699
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
699
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Association of genetic variations in genes implicated in the axis with outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with cetuximab plus chemotherapy.
    Miyamoto, Yuji
    Stintzing, Sebastian
    Heinemann, Volker
    Zhang, Wu
    Cao, Shu
    Okazaki, Satoshi
    Berger, Martin D.
    Suenaga, Mitsukuni
    Schirripa, Marta
    Soni, Shivani
    Matsusaka, Satoshi
    Ning, Yan
    Yang, Dongyun
    Gopez, Roel
    Melendez, Elizabeth
    Hanna, Diana L.
    Barzi, Afsaneh
    Baba, Hideo
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [42] Cetuximab plus FOLFIRI first line in patients (pts) with metastatic colorectal cancer (mCRC): A quality-of-life (QoL) analysis of the CRYSTAL trial
    Folprecht, G.
    Nowacki, M.
    Lang, I.
    Cascinu, S.
    Shchepotin, I.
    Maurel, J.
    Rougier, P.
    Cunningham, D.
    Zubel, A.
    Van Cutsem, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [43] Pharmacogenetic analysis in metastatic colorectal cancer (mCRC) patients (pts) treated with second-line irinotecan (IR)+/- cetuximab (CB): The EPIC experience
    Yang, D.
    Pohl, A.
    Zhang, W.
    Lurje, G.
    Ning, Y.
    El-Khoueiry, A.
    Khambata-Ford, S.
    Langer, C.
    Iqbal, S.
    Lenz, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [44] Tumor sidedness and enriched gene groups for efficacy of 1st-line cetuximab (cet) treatment in metastatic colorectal cancer (mCRC)
    Ichikawa, W.
    Mogushi, K.
    Lenz, H-J.
    Zhang, W.
    Tsuji, A.
    Takahashi, T.
    Denda, T.
    Shimada, K.
    Kochi, M.
    Nakamura, M.
    Kotaka, M.
    Segawa, Y.
    Lafleur, B.
    Luecke, J.
    Thompson, D.
    Moran, M.
    Astrow, S. H.
    Hsiang, J.
    Fujii, M.
    Sunakawa, Y.
    ANNALS OF ONCOLOGY, 2017, 28
  • [45] Impact of bevacizumab (bev) on overall survival (OS) in patients (pts) with metastatic colorectal cancer (MCRC): A population-based study
    Renouf, D. J.
    Lim, H. J.
    Speers, C.
    Villa, D.
    Gill, S.
    Blanke, C. D.
    O'Reilly, S. E.
    Kennecke, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [46] Effect of polymorphisms and miRNAs targeting CLOCK gene on gender-related survival in metastatic colorectal cancer (mCRC) patients (pts).
    Ruzzo, Annamaria
    Torsello, Angela
    Sperduti, Isabella
    Melucci, Elisa
    Giacomini, Elisa
    Mottolese, Marcella
    Fiorino, Roberta
    Zeuli, Massimo
    Pescarmona, Edoardo
    Magnani, Mauro
    Cognetti, Francesco
    Garufi, Carlo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [47] Polymorphisms and miRNAs targeting CLOCK gene affect gender-related survival in metastatic colorectal cancer (mCRC) patients (pts)
    Torsello, A.
    Ruzzo, A.
    Sperduti, I.
    Melucci, E.
    Giacomini, E.
    Mottolese, M.
    Fiorino, R.
    Zeuli, M.
    Pescarmona, E.
    Magnani, M.
    Cognetti, F.
    Garufi, C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S398 - S398
  • [48] Multiple treatment lines and prognosis for metastatic colorectal (mCRC) patients (pts)
    Rosanova, M.
    De Falco, S.
    Attademo, L.
    Fiore, G.
    De Stefano, A.
    Maddalena, C.
    De Placido, S.
    Carlomagno, C.
    ANNALS OF ONCOLOGY, 2017, 28
  • [49] Effects of capecitabine (X) an quality of life (QoL) in patients (pts) with metastatic colorectal cancer (MCRC).
    Beato, CAM
    Federico, MH
    Van Eyll, B
    Cabral, S
    Perdicaris, M
    Skare, NG
    Lago, S
    Carvalho, MP
    Moura, GL
    Duarte, RC
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 758S - 758S
  • [50] Capecitabine (X) improves quality of life (QoL) in patients (pts) with metastatic colorectal cancer (MCRC)
    Beato, Carlos
    Fedrico, M.
    Cabral, Sebastiao
    Durate, R.
    Van Eyll, B.
    Carvalho, M.
    Lago, Sergio
    Medeiros, E.
    Perdicaris, Martha
    MaChado, Denise
    ANNALS OF ONCOLOGY, 2004, 15 : 89 - 89
12345